Cargando…

Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study

BACKGROUND: Pharmacological treatment for chronic subdural hematoma (CSDH) recurrence prevention after surgery is under debate. CSDH may be related to suidoku (fluid disturbance) from the Japanese herbal kampo perspective. Goreisan (GRS) treats suidoku and is used to prevent a postoperative recurren...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsuki, Masahito, Kawamura, Shin, Koh, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Scientific Scholar 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345083/
https://www.ncbi.nlm.nih.gov/pubmed/35928329
http://dx.doi.org/10.25259/SNI_455_2022
_version_ 1784761353543614464
author Katsuki, Masahito
Kawamura, Shin
Koh, Akihito
author_facet Katsuki, Masahito
Kawamura, Shin
Koh, Akihito
author_sort Katsuki, Masahito
collection PubMed
description BACKGROUND: Pharmacological treatment for chronic subdural hematoma (CSDH) recurrence prevention after surgery is under debate. CSDH may be related to suidoku (fluid disturbance) from the Japanese herbal kampo perspective. Goreisan (GRS) treats suidoku and is used to prevent a postoperative recurrence. However, not all CSDHs are liquid, and some have structures such as trabecula, hematoma, and clots, suggesting oketsu (blood stasis). Therefore, we prospectively investigated the keishibukuryogan (KBG) effectiveness, which treats oketsu, for CSDH recurrence prevention and hematoma resolution compared to GRS. METHODS: We prospectively prescribed KBG 7.5 g/day for 12 CSDH patients after burr-hole surgery. As a control cohort, we retrospectively collected 48 patients treated by GRS 7.5 g/day. The recurrence within 1 month and the hematoma thickness after 1 month were evaluated. RESULTS: The median age was 84 years old. All the patients’ symptoms improved after surgery. The median preoperative midline shift and mean hematoma thicknesses were 6.0 mm and 23.75 mm. Those at 1 month were 2.0 mm and 11.43 mm. The recurrence rate was not significantly different between the KBG cohort (1 of 12) and the GRS cohort (4 of 48) (P = 0.999). The KBG’s noninferiority to GRS regarding the hematoma thickness at 1 month was statistically proven; KBG (12.26 mm) and GRS (11.20 mm). CONCLUSION: The recurrence rate at 1 month was not different between the KBG and GRS cohorts. The hematoma thickness at 1 month in the KBG cohort was not statistically inferior to that in the GRS cohort.
format Online
Article
Text
id pubmed-9345083
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Scientific Scholar
record_format MEDLINE/PubMed
spelling pubmed-93450832022-08-03 Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study Katsuki, Masahito Kawamura, Shin Koh, Akihito Surg Neurol Int Original Article BACKGROUND: Pharmacological treatment for chronic subdural hematoma (CSDH) recurrence prevention after surgery is under debate. CSDH may be related to suidoku (fluid disturbance) from the Japanese herbal kampo perspective. Goreisan (GRS) treats suidoku and is used to prevent a postoperative recurrence. However, not all CSDHs are liquid, and some have structures such as trabecula, hematoma, and clots, suggesting oketsu (blood stasis). Therefore, we prospectively investigated the keishibukuryogan (KBG) effectiveness, which treats oketsu, for CSDH recurrence prevention and hematoma resolution compared to GRS. METHODS: We prospectively prescribed KBG 7.5 g/day for 12 CSDH patients after burr-hole surgery. As a control cohort, we retrospectively collected 48 patients treated by GRS 7.5 g/day. The recurrence within 1 month and the hematoma thickness after 1 month were evaluated. RESULTS: The median age was 84 years old. All the patients’ symptoms improved after surgery. The median preoperative midline shift and mean hematoma thicknesses were 6.0 mm and 23.75 mm. Those at 1 month were 2.0 mm and 11.43 mm. The recurrence rate was not significantly different between the KBG cohort (1 of 12) and the GRS cohort (4 of 48) (P = 0.999). The KBG’s noninferiority to GRS regarding the hematoma thickness at 1 month was statistically proven; KBG (12.26 mm) and GRS (11.20 mm). CONCLUSION: The recurrence rate at 1 month was not different between the KBG and GRS cohorts. The hematoma thickness at 1 month in the KBG cohort was not statistically inferior to that in the GRS cohort. Scientific Scholar 2022-07-15 /pmc/articles/PMC9345083/ /pubmed/35928329 http://dx.doi.org/10.25259/SNI_455_2022 Text en Copyright: © 2022 Surgical Neurology International https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Katsuki, Masahito
Kawamura, Shin
Koh, Akihito
Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study
title Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study
title_full Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study
title_fullStr Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study
title_full_unstemmed Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study
title_short Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma – Prospective observational study
title_sort japanese herbal kampo medicine, keishibukuryogan, for chronic subdural hematoma – prospective observational study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9345083/
https://www.ncbi.nlm.nih.gov/pubmed/35928329
http://dx.doi.org/10.25259/SNI_455_2022
work_keys_str_mv AT katsukimasahito japaneseherbalkampomedicinekeishibukuryoganforchronicsubduralhematomaprospectiveobservationalstudy
AT kawamurashin japaneseherbalkampomedicinekeishibukuryoganforchronicsubduralhematomaprospectiveobservationalstudy
AT kohakihito japaneseherbalkampomedicinekeishibukuryoganforchronicsubduralhematomaprospectiveobservationalstudy